DLL3 and neoplasm: Based on preclinical data, both BiTE® molecules and CAR T cells have the potential for direct cell killing of DLL3-positive SCLC tumor cells, even at low levels of DLL3 cell surface expression (< 1000 receptors per cell) [39].